Skip to main content
S&P 5007,568.92+0.36%DOW51,786.72-0.38%NASDAQ25,372.01+0.83%BTC$77,151.00+0.27%ETH$2,264.75+0.41%GOLD$3,946.20+0.15%OIL$96.52+0.45%
Smart Investors Daily
SID Premium
Protalix BioTherapeutics, Inc. Common Stock logo

AMEX · PLX

Protalix BioTherapeutics, Inc. Common Stock

Healthcare · Biotechnology

$2.56

Up+$0.05 (+1.95%)

Updated Nov 4, 2026, 12:22 AM

SID Score

3.3/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
146.37M
P/E ratio
26.75
Dividend yield
0.00%
52-week range
$1.88 – $2.98
Volume
726.27K
Avg. volume
789.76K

Price performance · PLX

PLX price history

1M range · 0 trading sessions · Daily adjusted prices

PLX does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest PLX news

The latest Smart Investors Daily articles mentioning PLX.

Stock researchCompany · Overview

PLX research

Overview

Company profile and research snapshot.

Company profile

Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
PLX recent ratings
DateFirmRatingTarget
Sep 9, 2026HC Wainwright & Co.Buy—
Mar 19, 2026HC Wainwright & Co.Buy—
Nov 21, 2025HC Wainwright & Co.Buy—
Feb 3, 2025HC Wainwright & Co.Buy—
Nov 14, 2023HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 11, 2026

3 Oil And Gas Stocks to Watch as Supply Shock Risks Rise

Energy markets are running on a thinner safety cushion as emergency oil releases eat into strategic reserves and new buyers in Asia chase limited barrels. That mix creates real risk for future supply shocks and sharp price swings, along with potential openings for investors who understand which integrated oil and gas producers could benefit. This piece explains that backdrop and then highlights 3 stocks from our screener that are closely tied to this story. The three integrated producers...

Yahoo · Sep 8, 2026

Protalix BioTherapeutics to Participate in Upcoming September 2026 Investor Conferences

Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced that Gilad Mamlok, Senior Vice President and Chief Financial Officer, is scheduled to participate in the following two upcoming investor conferences in New York City, New York:

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By